? – Equity Guru Marketing Client

Falcon Gold (FG.V), up 60% on new properties, drills turning, and the novel tactic of ‘doing work’

Karim Rayani is a deal guy from way back, a non-stop money raiser, deal maker, handshaker and groover/shaker. If you needed a guy to invest in a biotech deal, Karim would go find him. If you needed some dough to kickstart a palladium mine, Karim will have a guy who knows a guy. And if you needed someone to write about your company, he’d be on the phone bothering me several times a day, squeezing me on my rate, selling me a tale that these guys. “My man, these guys, you have to meet them, they have something special. Sometimes it would even be special.

Read More »

Revive Therapeutics (RVV.C) warned about overhype, but up 26% on clinical trial news

Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.

Read More »

Heritage Cannabis (CANN.C) loses $2.3 million in Q4, finds extra year of runway as revenues kick in

A quick scan of headlines today would tell a harrowing story that Heritage Cannabis (CANN.C) was in big trouble and had lost $13 million and pandemonium had broken loose, and dogs and cats were going to be living together any time now. That’s because the company led their Q4 financials news release today with their yearly metrics filling the headlines, while their not-so-rough quarterly numbers were largely and inexplicably hidden from view.

Read More »

Equity Guru Podcasts